Halozyme Therapeutics (NASDAQ:HALO) Sets New 52-Week High at $57.21

Halozyme Therapeutics, Inc. (NASDAQ:HALO)’s stock price hit a new 52-week high during trading on Monday . The company traded as high as $57.21 and last traded at $57.21, with a volume of 2073 shares changing hands. The stock had previously closed at $56.23.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on HALO shares. The Goldman Sachs Group raised their price objective on Halozyme Therapeutics from $44.00 to $49.00 and gave the stock a “neutral” rating in a research note on Monday, July 22nd. Benchmark upped their price objective on shares of Halozyme Therapeutics from $50.00 to $60.00 and gave the company a “buy” rating in a research note on Tuesday, June 25th. Piper Sandler downgraded shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and lifted their target price for the stock from $48.00 to $51.00 in a research report on Friday, June 7th. Wells Fargo & Company upped their price target on shares of Halozyme Therapeutics from $48.00 to $58.00 and gave the company an “overweight” rating in a research report on Friday, June 7th. Finally, JMP Securities lowered their price objective on shares of Halozyme Therapeutics from $72.00 to $71.00 and set a “market outperform” rating on the stock in a research report on Wednesday, May 8th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $58.38.

Halozyme Therapeutics Trading Up 0.2 %

The company has a quick ratio of 5.36, a current ratio of 6.64 and a debt-to-equity ratio of 8.44. The business has a 50-day moving average of $50.25 and a 200-day moving average of $42.79. The stock has a market cap of $7.17 billion, a price-to-earnings ratio of 23.24, a PEG ratio of 0.57 and a beta of 1.27.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported $0.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.07. Halozyme Therapeutics had a return on equity of 225.71% and a net margin of 36.94%. The business had revenue of $195.88 million during the quarter, compared to analyst estimates of $201.72 million. As a group, research analysts forecast that Halozyme Therapeutics, Inc. will post 3.66 earnings per share for the current year.

Insider Transactions at Halozyme Therapeutics

In related news, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction on Wednesday, May 22nd. The shares were sold at an average price of $45.38, for a total value of $453,800.00. Following the completion of the sale, the senior vice president now owns 168,176 shares of the company’s stock, valued at approximately $7,631,826.88. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, CFO Nicole Labrosse sold 5,000 shares of the stock in a transaction dated Monday, July 22nd. The stock was sold at an average price of $53.93, for a total transaction of $269,650.00. Following the transaction, the chief financial officer now owns 15,480 shares of the company’s stock, valued at approximately $834,836.40. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Michael J. Labarre sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 22nd. The shares were sold at an average price of $45.38, for a total value of $453,800.00. Following the completion of the transaction, the senior vice president now directly owns 168,176 shares in the company, valued at $7,631,826.88. The disclosure for this sale can be found here. Insiders have sold a total of 45,000 shares of company stock worth $2,294,050 in the last 90 days. 2.40% of the stock is owned by insiders.

Hedge Funds Weigh In On Halozyme Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC lifted its stake in shares of Halozyme Therapeutics by 96.6% in the second quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 254 shares during the last quarter. Fifth Third Bancorp lifted its position in Halozyme Therapeutics by 2.4% during the 2nd quarter. Fifth Third Bancorp now owns 11,206 shares of the biopharmaceutical company’s stock worth $587,000 after acquiring an additional 261 shares during the last quarter. First Horizon Advisors Inc. boosted its holdings in Halozyme Therapeutics by 24.5% during the fourth quarter. First Horizon Advisors Inc. now owns 1,491 shares of the biopharmaceutical company’s stock valued at $55,000 after acquiring an additional 293 shares during the period. FCF Advisors LLC increased its stake in shares of Halozyme Therapeutics by 1.9% in the first quarter. FCF Advisors LLC now owns 21,164 shares of the biopharmaceutical company’s stock worth $861,000 after purchasing an additional 391 shares during the period. Finally, New York State Teachers Retirement System increased its stake in shares of Halozyme Therapeutics by 0.4% in the first quarter. New York State Teachers Retirement System now owns 113,820 shares of the biopharmaceutical company’s stock worth $4,630,000 after purchasing an additional 400 shares during the period. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.